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Objective: This study sought to examine the prognostic value of heart rate variability (HRV) 
measurement initiated immediately after emergency department presentation for patients with 
acute coronary syndrome (ACS).
Background: Altered HRV has been associated with adverse outcomes in heart disease, but 
the value of HRV measured during the earliest phases of ACS related to risk of 1-year rehos-
pitalization and death has not been established.
Methods: Twenty-four-hour Holter recordings of 279 patients with ACS were initiated within 
45 minutes of emergency department arrival; recordings with 18 hours of sinus rhythm were 
selected for HRV analysis (number [N] 193). Time domain, frequency domain, and nonlinear 
HRV were  examined. Survival analysis was performed.
Results: During the 1-year follow-up, 94 patients were event-free, 82 were readmitted, and 
17 died. HRV was altered in relation to outcomes. Predictors of rehospitalization included 
increased normalized high frequency power, decreased normalized low frequency power, and 
decreased low/high frequency ratio. Normalized high frequency 42 ms2 predicted rehospital-
ization while controlling for clinical variables (hazard ratio [HR] 2.3; 95% confidence interval 
[CI] 1.4–3.8, P 0.001). Variables significantly associated with death included natural logs of 
total power and ultra low frequency power. A model with ultra low frequency power 8 ms
2 
( HR 3.8; 95% CI 1.5–10.1; P 0.007) and troponin 0.3 ng/mL (HR 4.0; 95% CI 1.3–12.1; 
P 0.016) revealed that each contributed independently in predicting mortality. Nonlinear HRV 
variables were significant predictors of both outcomes.
Conclusion: HRV measured close to the ACS onset may assist in risk stratification. HRV 
 cut-points may provide additional, incremental prognostic information to established assessment 
guidelines, and may be worthy of additional study.
Keywords: autonomic cardiac function, coronary artery disease, outcomes research, risk 
assessment, hospital readmittance, mortality
Introduction
Identification of patients at increased risk for rehospitalization or death within a year of 
presenting to the emergency department (ED) with acute coronary syndrome (ACS) (ie, 
diagnosis of ST elevation myocardial infarction, non-ST elevation myocardial infarction, 
or unstable angina (UA), can help guide ongoing therapy. Safe, cost- effective, and read-
ily available tools to aid in risk assessment are needed. Heart rate variability (HRV) is a 
measure derived from noninvasive cardiac monitoring that reflects autonomic cardiac 
function1,2 and may provide insight into patients’ ability to recover from physiological 





insult, such as myocardial infarction (MI) or an episode of 
UA. In a 1987 study by Kleiger et al,3 the standard devia-
tion of normal sinus RR intervals (SDNN), measured using 
24-hour Holter  recordings, was associated with all-cause 
death in the post-MI population.3 Subsequent research has 
supported the association of decreased HRV and mortality 
in patients with cardiovascular disease.4–8 Less is known, 
however, about the prognostic value of HRV measurement 
initiated within the first hour of ED presentation during the 
earliest phases of ACS, particularly in association with risk 
of rehospitalization (Table 1 provides a list of HRV variable 
definitions).
The primary aims of this study were to answer the follow-
ing questions in patients presenting to the ED with ACS:
1. Is HRV measured during the 24 hours after ED arrival 
predictive of 1-year all-cause:
a. rehospitalization; or
b. death?
2. Which HRV variables, if any, may serve as clinically 
useful tools to aid in risk stratification for ACS patients 
over the course of a 1-year follow-up period?
Methods
Research design and sample
A secondary analysis was performed of electrocardio-
graphic (ECG) data from the Ischemia Monitoring and 
Mapping in the Emergency Department In Appropriate 
Triage and Evaluation of Acute Ischemic Myocardium 
(IMMEDIATE AIM) study,9 a prospective clinical trial of 
patients who presented to the ED of a large urban hospi-
tal with symptoms of ACS (number [N] 1,308), funded 
by the National Institutes of Health, Washington DC, 
United States (RO1HL69753). We enrolled patients from 
2002–2004. Each patient was followed for 1 year, and the 
study ended in 2005. Patients’ verbal assent was obtained in 
the ED, and written consent was obtained from the patient or 
the patient’s surrogate after the patient stabilized. The Uni-
versity of California, San Francisco (CA, USA) institutional 
review board approved the study.
Data collection
Twenty-four-hour Holter recorders (HScribe™ System, 
Mortara Instrument, Inc., Milwaukee, WI, USA) were placed 
within minutes of ED arrival (median “door-to-Holter” time, 
44 minutes). The sampling rate was 180 samples/second. 
Research nurses applied ECG leads, supervised monitor-
ing, and downloaded data to the HScribe review station. 
 Radiolucent electrodes and lead wires were used to aid in 
uninterrupted monitoring, including during chest  radiography 
and cardiac catheterization procedures. Patients’ demo-
graphic and clinical information was gathered upon enroll-
ment or extracted later via chart review.
Follow-up
Nurses followed patients for 1 year after their ED visit. 
 Discharge diagnoses, determined in accordance with crite-
ria of cardiovascular disease in the International  Statistical 
 Classification of Diseases and Related Health  Problems,10 




Definition (units) (all variables are computed  
over the entire recording time of approximately 
24 hours)
Time domain variables1,2
SDNN Standard deviation of all normal RR intervals (ms)
SDANN Standard deviation of the average of normal RR 
intervals in all 5-minute segments (ms)
Frequency domain variables1,2
TPlog* Total power (ms
2)
HFlog* Average of 5-minute segments of high-frequency 
power (ms2)
LFlog* Average of 5-minute segments of low-frequency 
power (ms2)
VLFlog* Very low-frequency power, averages of 5-minute 
segments (ms2)
ULFlog* Ultra-low-frequency power (ms
2)
NHF** Normalized 5-minute intervals of high-frequency 
power (nu)
NLF** Normalized 5-minute segments of low-frequency 
power (nu)
LF/HFlog* **Average of 5-minute segments of normalized low-/
high-frequency ratio (ratio)
Nonlinear measures6,8,12–14
DFA1 Detrended fluctuation analysis: short-term fractal 
scaling exponent calculated over 3–11 beats, 
averaged 
Over 1,000 beats for 24 hours, also known as alpha 1 
or 1 (exponent value)
SD12 From the Poincaré plot, the ratio of the dispersion, or 
standard deviation, perpendicular to the line-of-identity 
axis (approximately lower left to upper right), indicating 
short-term, instantaneous beat-to-beat variance versus 
the standard deviation of the diagonal axis, indicating 
long-term, continuous variance also know as the SD1/
SD2 (ratio)





Very low frequency (0.003–0.04 Hz) 
 
Ultra-low frequency ( 0.003 Hz)
Notes: *Natural log transformations were performed for variables that were 
not normally distributed. **normalized units (nu), appropriate for high frequency 
and low frequency only, represent the relative value of each power component 
in proportion to the total power without the very low frequency component.14 
High frequency nu 100%  high frequency/(high frequency  low frequency). Low 
frequency nu 100%  low frequency/(high frequency  low frequency).




Heart rate variability in ACS
were identified from medical records. Data regarding 
patients’ hospital readmissions and survival were collected 
via telephone calls, medical records, and/or the public access 
social security mortality database. Using at least one of these 
avenues, 1-year survival and rehospitalization information 
was obtained for all patients in the current analysis. When 
possible, the patient’s report of a cardiac cause for rehospi-
talization was corroborated with the medical record.
Inclusion and exclusion criteria
Only ECG recordings with 18 hours or more were included. 
These recordings represented patients who were admitted 
to the hospital to rule out MI. If a patient was admitted 
more than once during the study enrollment period, only the 
recording for the first admission was included. Patients who 
were positively diagnosed with ACS by time of discharge 
were selected for analysis (N 193). Since HRV requires 
normal sinus rhythm to evaluate,1 recordings of patients with 
atrial fibrillation or paced rhythms were excluded. Figure 1 
is a flowchart of the inclusion process.
Endpoints
Primary outcomes were all-cause rehospitalization or 
death between ED discharge and end of follow-up. Patients 
who returned to the hospital and subsequently died before 
year’s end were included in the analyses of mortality only. 
Rehospitalizations and/or deaths due to cardiac causes, ie, 
a recurring ACS episode and/or heart failure, were also 
documented.
Demographic and clinical variables
Variables chosen for the analysis included established risk 
factors11 and potential confounders of outcomes. Among 
the variables chosen for examination were sex, race, cat-
egory of ACS diagnosis, comorbidities (such as diabetes or 
hypertension), history (such as previous diagnosis of coro-
nary artery disease [CAD]), clinical factors (such as peak 
troponin and ST changes), social factors (such as smoking 
status), living situation (alone or with another person), ACS 
therapies (such as beta blocker administration or reperfu-
sion procedure within 90 minutes of ED arrival), and events 
during the course of hospitalization, including surgery or 
complications (such as cardiac arrest) (see Table 2). Age was 
examined both as a continuous variable and as a categorical 
variable, dichotomized at 65 years as per the Thrombolysis 
in Myocardial Infarction risk score.11 MI and UA diagnoses 
were examined together, and then separately, in relation to 
HRV variables and outcomes.
Heart rate variability analysis
HScribe™ analysis software (Mortara Instruments, Inc.) 
located at the ECG Monitoring Research Laboratory, 
 University of California, San Francisco, School of Nursing 
(San Francisco, CA, USA) displayed the waveforms. All ECG 
1) Positive ACS diagnosis
2) ECG recording represents unique patient
3) Greater than or equal to 18 hours of
     recording time
4) Recording represents patient with
     predominantly (>80%) sinus rhythm
5) At least 80% analyzable ECG data
    (ie, sinus rhythm without premature beats,
    artifact, or noisy signal)
Inclusion criteria
Heart rate variability
and 1-year ACS outcomes,
N=193
193 patient recordings with greater than 80%
analyzable ECG signals




298 recordings of patients positively
diagnosed with acute coronary syndrome
203 patient recordings with predominantly
(greater than 80%) sinus rhythm
Immediate aim: patients present to
emergency department with symptoms of
acute coronary syndrome
N=1,308
Figure 1 Flow chart for inclusion in the analysis of heart rate variability and 1-year outcomes in an ACS study.
Note: Immediate aim: ischemia monitoring and mapping in the emergency department during appropriate triage and evaluation of acute ischemic myocardium.
Abbreviations: N, total number; ACS, acute coronary syndrome; ECG, electrocardiography.





recordings were automatically scanned and manually edited 
by one researcher to maintain uniformity and to ensure that 
only normal-to-normal beats were included in the analyses. 
Beat-to-beat files were generated. HRV research software, 
validated by the Heart Rate Variability  Laboratory, Wash-
ington University School of Medicine, St Louis, MO (USA), 
verified the eligible recordings, and used an algorithm to 
compute time domain, frequency domain, and nonlinear 
variables.
Time-domain measurements were computed using 
descriptive statistical methods. To evaluate HRV variables 
in the frequency domain, Fast Fourier transform spectral 
analysis was performed.1 From the start of the recording time, 
5-minute intervals were segmented. All intervals with at least 
75% of analyzable data – ie, those that displayed at least 75% 
normal sinus rhythm – were used. Overall, a recording needed 
to have at least 75% or 18 hours of analyzable rhythm to be 
included in the analysis.
To assess nonlinear HRV properties, two variables were 
selected: the short-term fractal-scaling exponent (DFA1); 
and the Poincaré ratio (SD12). DFA1 was computed using 
detrended fluctuation analysis, a method that takes into 
account changing conditions over time and is applicable of 
analyzing physiologic signals.12–13 Poincaré plots are graphic 
representations of coordinates corresponding to consecutive 
normal RR intervals, and were generated for each patient 
Table 2 Demographic and clinical characteristics in relation to 1-year outcomes
Variable N of all ACS patients 
n (% of total N)
All-cause outcomes Event-free
Rehospitalized Died
N 193 82 17 94
Mean age in years 65 13 66 12 71 17 64 12
Male sex, n 110 (57%) 40 9 61
Race, n 
  American Indian/Alaskan Native 
Black/African American 






















ACS discharge diagnosis, n 



















History or comorbidity, n 

























  Mean  SD peak troponin I, ng/dL 
Mean  SD maximum ST elevation, microvoltsa 
Mean  SD maximum ST depression, microvoltsa 
Chest pain on arrival to the emergency department, n 

























Social factors, n 
  Nonsmoker 




























Events during the course of hospitalization, n 
  Percutaneous coronary intervention (not early) 
CABG during the course of hospitalization 
Complications during hospitalizationc 





















Notes: aMean maximum ST elevation or depression, as measured on the initial emergency department 12-lead electrocardiogram; bearly reperfusion refers to thrombolytic 
or percutaneous coronary intervention within 90 minutes of emergency department presentation; ccomplications during hospitalization other than death: cardiac arrest; 
cardiogenic shock; severe heart failure; extension of myocardial infarction; new myocardial infarction; transfer from admission unit due to acute instability. Percentages are 
rounded to the nearest whole number.
Abbreviations: N, total number; n, sample number; ACS, acute coronary syndrome; STEMI, ST segment elevation myocardial infarction; SD, standard deviation; 
CABG, coronary artery bypass graft; Non-STEMI, Non ST elevation myocardial infarction; ng, nanograms.
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to visualize HRV organization and explore nonlinear HRV 
characteristics. The Poincaré ratio is the ratio of axes of an 
ellipse fitted to the plot (SD1 short axis/SD2 long axis, 
ratio SD12), reflecting short-term, beat-to-beat variation 
compared to long-term, continuous variation.7,15–17
HRV variables chosen for the analysis were based upon 
published standards1 and previous research.3–8,12–21 See Table 1 
for additional details about HRV.
Statistical analyses
Descriptive statistics assessed demographic and clinical 
 variables. Variables without normal distribution were trans-
formed using natural logs.7,21 Discharge diagnoses of UA or MI in 
relation to outcomes were examined using the chi-square test.
Simple Cox regression univariate survival analyses were 
performed for each HRV, demographic, and clinical variable to 
assess proportional hazards across time. With the exception of 
the known risk factors of age and sex,11 only clinical or demo-
graphic variables identified during the univariate analyses with 
P 0.10 were included in the multivariate analyses. Table 3 
shows the results of the simple or univariate analyses for the 
clinical and demographic variables. HRV variables were then 
retested in models with the identified demographic and clini-
cal risk factors (alpha 0.05). Highly correlated variables 
(r 0.7) were not tested within the same model.
To identify meaningful HRV cut-points in relation to 
outcomes, receiver–operator curves were generated. High 
sensitivity and specificity provided a reference value for 
systematically assessing variables in relationship to each 
outcome by maximizing the log likelihood in simple Cox 
regression analyses. In multivariate models, age and sex 
were retained as potentially relevant predictors, and back-
ward elimination further assisted in identifying the most 
significant prognostic contributors. Significant categorical 
HRV variables were examined and tested for interactions 
with covariates. Bootstrapping (1,000 samples; 95% con-
fidence interval [CI]) was used to examine model stability 
(alpha 0.05).22 Harrell’s cumulative index (C-statistic) was 
calculated to evaluate the models’ predictive ability.  Analyses 
were performed using IBM statistical software (SPSS 19; 
IBM Corporation, Armonk, NY, USA).
Results
Patient characteristics and outcomes
Median ECG recording time was 1,439 minutes. Median 
follow-up for survivors was 369 days. Patient characteristics 
are in Table 2. Ninety-four patients (48.7%) had event-free 
outcomes. Eighty-two patients (42.5%) were readmitted for 
any cause; 67 had a cardiac diagnosis (82% of readmissions). 
Of the 15 patients who were readmitted for any cause, but 
that were not cardiac related, nine had a comorbidity of 
diabetes. Seventeen patients (8.8%) died, 13 due to cardiac 
causes (76.5% of deaths).
Chi-square analysis revealed that all-cause death within 
1 year was significantly more prevalent in patients diagnosed 
with MI as opposed to those with UA (P 0.003; odds ratio: 
4.372; 95% CI 1.536–12.444). However, the ACS diagnostic 
group was not a significant factor in prevalence of all-cause 
rehospitalization. Similarly, chi-square analysis did not show 
that cardiac death or cardiac rehospitalization was  significantly 
related to ACS diagnosis. Significant  univariable Cox regression 
results for demographic and clinical variables are in Table 3.
Continuous HRV and 1-year  
rehospitalization
Simple Cox regression analyses demonstrated that decreased 
normalized low frequency (NLF), low/high frequency ratio 
(LF/HF), natural log of very LF, and DFA1 were significant 
predictors of all-cause rehospitalization, as were elevated 
normalized HF (NHF) and SD12 (Table 4). Simple Cox 
regression analyses also showed that when hospitalization 
was limited to those who were admitted for cardiac causes 
(67 events, no deaths), decreased NLF  (hazard ratio [HR] 
0.983; 95% CI 0.968–0.997; P 0.021), decreased natural 
log of the LF/HF (LF/HFlog) (HR 0.688; 95% CI 0.498–
0.950; P 0.023), and increased NHF (HR 1.026; 95% CI 
1.006–1.046; P 0.012) remained significant  predictors. 
Other HRV variables were not significantly different in rela-
tion to rehospitalization outcomes.
In chi-square analyses of the 15 patients rehospitalized 
for a noncardiac reason, a diabetes diagnosis was signifi-
cantly related to hospital readmission (Pearson’s chi-square, 
14.614; P 0.001).
NHF, NLF, LF/HF, DFA1, and SD12 continued to be 
significant predictors in conjunction with age, sex, living situ-
ation, diabetes, and history of CAD in multivariate analysis. 
 Predictive power ranged from 74%–76% (Table 5). When 
patients diagnosed with UA were examined alone in the 
multivariate Cox regression model, continuous NHF was a 
significant independent predictor of all-cause rehospitaliza-
tion (P 0.028).
Continuous HRV and 1-year mortality
In simple Cox regression analyses, lower standard deviation 
of the average SDANN (standard deviation of the average of 
normal RR intervals in all 5-minute segments), natural logs 





maximized at NHF 42 normalized units (nu) (HR 2.60; 
95% CI 1.66–4.07; P 0.001). Chi-square analysis showed 
that this cut-point had a sensitivity of 39% and specificity 
of 88%, a positive predictive value of 74%, and a negative 
predictive value of 63% (chi-square 17.708, P 0.001). 
Table 3 Significant demographic or clinical variables and 1-year 
outcomes
Clinical variable Adverse all-cause 1-year outcomes
Rehospitalization Died
Hazard ratio  
(95% CI)
P-value
Hazard ratio  
(95% CI)
P-value
Simple Cox regression results ( 0.10)
Total N N 176 (no deaths) 
n with event 82
N 193 
n with event 17
Potential risk factors




 Female sex 1.506 (0.977–2.323) 
P 0.064
NS
 Race: African American 1.967 (1.213–3.191) 
P 0.006*
NS
 Myocardial infarction NS 3.937 (1.456–10.648) 
P 0.007*
 Diabetes comorbidity 2.204 (1.412–3.439) 
P 0.001*
NS





  Increased peak  
troponin (ng/mL)
NS 1.290 (1.043–1.594) 
P 0.019*,c
  Increased maximum  
ST elevation 
(natural log)
NS 1.663 (1.055–2.619) 
P 0.028*
  Decreased maximum  
ST depression*
NS 1.037 (1.006–1.070) 
P 0.018*





 Early reperfusion NS 3.202 (0.919–11.151) 
P 0.068
Potential protective factors
  Chest pain reported in 
emergency department
NS 0.303 (0.087–1.054) 
P 0.060





Notes: aHazard ratio is based upon age, dichotomized at 65 years per Thrombolysis 
In Myocardial Infarction risk score;21 bhazard ratio is based upon ascending age 
per decade; chazard ratio is based on ng/mL ascending in increments of ten units; 
*significant P-values 0.05.
Abbreviations: CI, confidence interval; N, total number; n, sample number; NS, 
not statistically significant.
Table 4 Significant continuous HRV variables and 1-year 
outcomes
Variable 
Please see Table 1 for HRV 
variable definitions
Rehospitalization Died
Hazard ratio  
(95% CI) 
P-value
Hazard ratio  
(95% CI) 
P-value
Simple Cox regression results ( 0.10)
Total N N 176 (no deaths) 
n with event 82
N 193 
n with event 17
HRV variables
  Decreased standard  
deviation of all normal  
RR intervals (SDNN)*
NS 1.176  
(0.983–1.406) 
P 0.075
  Decreased standard  
deviation of the average of  
normal RR intervals in all 
5-minute segments (SDANN)*
NS 1.253  
(1.001–1.567) 
P 0.049**
  Decreased total power  
(natural log)
NS 2.257  
(1.065–4.785) 
P 0.034**






  Decreased ultra-low  
frequency (natural log)
NS 2.183  
(4.425–1.076) 
P 0.030**












  Decreased low frequency/ 






  Decreased short-term  
















Additional ECG monitoring variables
  Increased mean heart  
rate*
NS 1.606  
(1.106–2.331) 
P 0.013**
  Increased number of  






Notes: “Decreased” indicates that lower values are associated with increased risk. 
“Increased” indicates that higher values are associated with increased risk. *Hazard 
ratio reported as a change in increments of ten units; **statistically significant 
P-values 0.05.
Abbreviations: HRV, heart rate variability; CI, confidence interval; N, total number; 
n, sample number; NS, not statistically significant; ECG, electrocardiography; 
VPC, ventricular premature contractions.
of total power (TPlog) and ultra LF power (ULFlog), and DFA1 
were significantly associated with death. Higher SD12 was 
also significantly associated (Table 4). Other HRV variables 
were not significantly different in conjunction with survival. 
In an examination of mortality with UA patients alone, HRV 
was not a significant predictor.
HRV cut-points and 1-year  
rehospitalization
A receiver operator curve showed that the area under the curve 
for NHF was 0.67 (P 0.041) with higher values associated 
with rehospitalization. A systematic assessment of cut-points 
using simple Cox regression revealed the log likelihood was 




Heart rate variability in ACS
Tested in the same manner, lower NLF was associated with 
rehospitalization, area under the curve 0.67 (P 0.040). 
NLF 50 nu maximized the log likelihood (HR 1.975; 
95% CI 1.28–3.05) of rehospitalization. Sensitivity was 
70%, specificity was 51%, the positive predictive value 
was 62%, and the negative predictive value was 60% (chi-
square 8.398; P 0.004). This method also identified the LF/
HFlog ratio, DFA1, and SD12 cut-points; multivariate Cox 
regression analysis results are in Table 5.
HRV cut-points and 1-year mortality
HRV cut-points associated with  mortali ty were 
de te rmined  in  a  s imi la r  fash ion  to  those  for 
 rehospitalization. In simple Cox regression models, low 
SDANN 53 ms (HR 3.654; 95% CI 1.390–9.603; P 0.009), 
TPlog 8.4 ms
2 (HR 3.71; 95% CI 1.43–9.62; P 0.007), 
ULFlog 8.0 ms
2 (HR 3.70; 95% CI 1.39–9.60; 
P 0.009), and high SD12 0.45 ratio (HR 3.358; 95% 
CI 1.296–8.706; P 0.013) were significant predictors of 
all-cause 1-year mortality.
Clinical risk model for 1-year  
rehospitalization
An interaction was found between NHF dichotomized at 42 nu 
and diabetes (HR 2.667; 95% CI 1.08–6.62; P 0.034). 
The consistency of the interaction remained significant 
when diabetes was tested using NHF as a continuous 
 variable (P 0.008). Combining NHF dichotomized at 
42 nu and diabetes created a variable with four categories. 
Cox  regression analysis showed that patients with either 
NHF 42 nu or diabetes were more likely to return to the 
hospital than patients without either of those conditions. 
Patients with both conditions were even more likely to return 
(Figure 2).
Similarly, patients with a history of CAD and NLF 50 nu 
were more likely to be readmitted than patients without either 
condition, or with one condition alone (Figure 3).
Clinical risk model for 1-year mortality
Patients diagnosed with MI were at higher risk for mortal-
ity according to our chi-square findings, leading us to an 
examination of HRV in conjunction with cardiac troponin. 
In a Cox regression model, ULFlog 8 ms
2 (HR 3.822; 95% 
CI 1.452–10.060; P 0.007) and peak Troponin I 0.3 nm/mL 
(HR 3.956; 95% CI 1.288–12.144; P 0.016) were 
strong independent predictors of death (model chi-square 
14.625; P 0.001). Peak cardiac troponin of 0.3 ng/mL 
was used as the cut-point for analysis per the local labora-
tory standard definition of myocardial injury at the time of 
data collection.
In a second analysis, dichotomized ULFlog 8 ms
2 and 
peak troponin 0.3 ng/mL were categorized into four 
groups (low to high risk), and served to examine the rela-
tionship of these variables with all-cause death (Figure 4). 
 Fourteen out the 17 nonsurvivors, including ten of 13 cardiac 
Table 5 HRV, clinical variables, and all-cause 1-year rehospitalization – continuous and dichotomized HRV and five clinical variables in 
multivariate Cox regression and C-statistic
Clinical variables: older age, female sex, living with a significant other, history of coronary artery disease, diabetes (C-statistic for  
five clinical variables without HRV variables 0.735)
Variable Hazard ratio 95% confidence  
interval
P-value C-Statistic
Decreased normalized low frequency* 
(lower values linked with higher risk)
1.253 1.091–1.471 0.006 0.758
Normalized low frequency 50 ms2 1.721** 1.071–2.764** 0.025** 0.746**
Increased normalized high frequency* 
(higher values linked with higher risk)
1.370 1.121–1.675 0.002 0.762
Normalized high frequency 42 ms2 2.299** 1.399–3.774** 0.001** 0.765**
Decreased low/high frequency ratio 1.597 1.134–2.232 0.006 0.755
Low/high frequency ratio 0.5 
(lower values linked with higher risk)
1.787** 1.101–2.902** 0.019** 0.745**
Decreased short-term fractal scaling exponent  
(DFA1) (lower values linked with higher risk)
3.175 1.321–7.634 0.010 0.757
Short-term fractal scaling exponent (DFA1) 0.95 1.776** 1.096–2.878** 0.020** 0.749**
Increased Poincaré ratio (SD12) (higher values  
linked with higher risk)
5.408 1.304–22.427 0.020 0.752
Poincaré ratio (SD12) 0.45 1.816** 1.077–3.060** 0.025** 0.741**
Notes: *Reported in increments of ten units; **dichotomized variables.
Abbreviation: HRV, heart rate variability.
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Figure 2 Normalized HF heart rate variability and diabetes: risk of rehospitalization within 1 year of presentation to the emergency department with acute coronary 
syndrome.
Notes: Neither risk factor: no diabetes and normalized high-frequency 42 nu. Both risk factors: diabetes diagnosis and normalized high frequency 42 nu. Model chi-
square 26.77 (P 0.001).
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Figure 3 Normalized LF heart rate variability and CAD history: risk of rehospitalization within 1 year of presentation to the emergency department with acute coronary 
syndrome.
Notes: Neither risk factor: no history of coronary artery disease and normalized LF 50 nu. Both risk factors: history of coronary artery disease and normalized LF 50 nu. 
Model chi-square 14.26 (P 0.004).
Abbreviations: CAD, coronary artery disease; LF, low frequency power; nu, normalized units. 
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deaths, were identified by values of ULFlog 8 ms
2 and/or 
 troponin 0.3 ng/mL. Presence of the two variables together 
proved to be a stronger predictor of death than either vari-
able alone.
SDANN 53 ms (HR 3.63; 95% CI 1.38–9.55; 
P 0.009) and cardiac troponin 0.3 ng/mL (HR 3.79; 
CI 1.24–11.64) (model chi-square 14.197; P 0.020) pro-
vided another predictive model for all-cause mortality (model 
chi-square, P 0.001), as did TPlog 8.4 ms
2 (HR 3.65; 
95% CI 1.41–9.48; P 0.008) and troponin 0.3 ng/mL 
(HR 3.54; 95% CI 1.23–11.53; P 0.021) (model chi-
square 14.559; P 0.001).
Cardiac outcomes
Seventy-three rehospitalizations and 13 deaths were attrib-
uted to cardiac causes. Cox regression analyses revealed that 
NLF power (P 0.006), NHF power (P 0.004), LF/HF ratio 
(P 0.006), and DFA1 (P 0.031) were significantly associated 
with cardiac rehospitalization in univariate analysis. NHF power 
(P 0.031) and LF/HF ratio (P 0.047) remained significant in 
the multivariate analyses with age, sex,  comorbidity of diabetes, 
prior history of CAD, and  living with a significant other. These 
relationships remained significant in bootstrap models.
Thirteen deaths within the first year were due to cardiac 
causes. When cardiac mortality alone was examined, low 
SDNN (HR 0.764; 95% CI 0.608–0.958; P 0.020), 
SDANN (HR 0.712; 95% CI 0.536–0.946; P 0.019), TPlog 
(HR 0.298; 95% CI 0.123–0.718; P 0.007), and ULFlog 
(HR 0.323; 95% CI 0.142–0.735; P 0.007) were significant 
predictors. Again, significant relationships were maintained in 
bootstrap models. Other HRV variables were not significantly 
different in conjunction with cardiac survival.
Poincaré plots
Elevated Poincaré ratio, SD12, was a significant predictor 
of both rehospitalization and death; SD12 0.45 was sig-
nificant for both outcomes. Poincaré plots provided a visual 
representation of SD12 and HRV organization for each 
patient. To illustrate organizational differences, the plots for 
three patients are depicted in Figure 5. Each row documents 
three 1-hour periods during the 24-hour recording time. 
SD12 for each hour is recorded to the left of each plot. Row 
A  represents a UA patient who has elevated NHF power and 
was rehospitalized. The plot is clustered high and to the right. 
Row B represents a patient diagnosed with non-ST elevation 
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Figure 4 Ultra-low frequency heart rate variability and cardiac troponin: risk of death within 1 year of presentation to the emergency department with acute coronary 
syndrome.
Notes: Neither risk factor: troponin I 0.3 ng/mL and ULFlog 8 ms
2. Both risk factors: troponin I 0.3 ng/dL and ULFlog 8 ms
2. Model chi-square 22.640 (P 0.001).
Abbreviations: ULFlog, ultra-low frequency power (natural log transformation); UFL, ultra-low frequency power; nu, normalized units; ng, nanogram; dL, deciliter.





suggestive of disease.14 Row C represents a patient diagnosed 
with UA who remained event-free. The plot shape is similar 
to that of a healthy person.14
Discussion
Numerous studies have shown that altered HRV is associ-
ated with autonomic dysfunction and worse outcomes in 
patients with cardiac disease,3–8,15–20 and is even linked to 
increased cardiovascular risk in older adults without previ-
ously recognized problems.13,14,21 The value of HRV in ACS 
prognosis has been demonstrated, and HRV is a class 2b 
recommendation for the assessment of ventricular arrhyth-
mias in patients with ST-elevation MI.23 However, it is not 
included in recommendations for non-ST-elevation MI or 
UA. We believe that that the innovation of our study lies in 
the very early initiation of ECG Holter recording – within 
the first hour of ED arrival – and it demonstrates that HRV 
measured during the first 24 hours after ED presentation, even 
with the possibility of hemodynamic instability and increased 
sympathetic activation, provides an excellent opportunity to 
obtain this vital information.
Additionally, HRV in relation to ACS patients without 
MI and their 1-year rehospitalization outcomes deserve 
further attention. In hospitalized UA patients, Huang et al24 
found that transient ST depression and silent ischemia were 
associated with lower HRV. Patients who stabilized showed 
improvements in HRV after admission. SDNN 50 ms was 
significantly associated with four deaths during the ensuing 
Hourly poincaré plots with ratios and mean 24-hour Holter
measurements
NHF =59.83 nu, NLF =23.59 nu, TPlog =9.21 ms
2, ULFlog =9.03 ms
2, DFA1=0.4772, SD12=0.7221
Patient A  Diagnosis: unstable angina; status: rehospitalized; mean 24-hour HRV:
TPlog =9.65 ms
2, ULFlog =9.55 ms
2, DFA1=1.140, SD12=0.2707
Patient C  Diagnosis: unstable angina; status: event-free; NHF =32.61 nu, NLF =57.93 nu, 
NHF =26.64 nu, NLF =49.08 nu, TPlog=7.86 ms
2, ULFlog=7.57 ms
2, DFA1=0.7437, SD12=0.4655




















































Figure 5 HRV illustrated with Poincaré plots: 1-hour Poincaré plots, 9–10 PM, 5–6 AM, and 1–2 PM in three patients with different outcomes.
Notes: X-axis: RR(n) interval duration (ms). Y-axis  RR(n 1) interval duration (ms). X and Y axes each represent 400–1,600 ms. SD1  dispersion (standard deviation) 
perpendicular to the line of the identity axis; represents beat-to-beat instantaneous variance in RR intervals. SD2  dispersion (standard deviation) along the line-of-identity 
axis, or approximately from the lower left to the upper right; represents long-term continuous variance in RR intervals.
Abbreviations: SD12, SD1/SD2 ratio, From the Poincaré plot, the ratio of the dispersion, or standard deviation, perpendicular to the line-of-identity axis (approximately 
lower left to upper right), indicating short-term, instantaneous beat-to-beat variance versus the standard deviation of the diagonal axis, indicating long-term, continuous 
variance also know as the SD1/SD2 (ratio); HRV, heart rate variability; NHF, normalized high-frequency power; NLF, normalized low-frequency power; TPlog, total power 
log; ULFlog, natural log transformation of ultra-low frequency power; DFA1, detrended fluctuation analysis, short-term fractal scaling exponent; MI, myocardial infarction; 
nu, normalized units.
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11 months (P 0.0001).24 In addition, Carpeggiani et al6 mea-
sured HRV with Holter monitors that were initiated 48 14 
hours after admission in MI patients. The main endpoints 
were in-hospital complications; low LF power was found 
to be a significant predictor.6 Lanza et al25 collected data 
from 1997–2001 using Holter recordings that were started 
within 24 hours of hospital admission in 543 UA patients. 
Primary endpoints were in-hospital and 6-month deaths, and 
a secondary endpoint was nonfatal acute MI. The mean of 
the standard deviations of RR intervals for all 5-minute seg-
ments in 24 hours (called the SDNN index) and LF power 
were significantly associated with in-hospital mortality in 
multivariate analysis. LF power and the LF/HF ratio were 
associated with 6-month mortality. HRV was not significantly 
associated with nonfatal outcomes.
While evidence shows that HRV can be altered in UA 
patients, the changes in relation to 1-year outcomes need 
further investigation. To our knowledge, this is the first study 
to show that HRV measurements derived from 24-hour Holter 
recordings started within the first hour of ED presentation 
in patients with evolving ACS (a period of time likely to 
be associated with a high level of sympathetic activation), 
including both UA and MI diagnoses, are associated with 
1-year all-cause rehospitalization and mortality. 
1-year all-cause rehospitalization
Hospital readmittance after an ED visit with an ACS diag-
nosis is common and contributes directly to the economic 
burden of health care. Johnston et al26 studied insurance 
claims of 30,200 ACS patients between 2002–2007; even 
one cardiac rehospitalization within a year of the initial ED 
presentation increased cost of care by nearly $10,000 USD 
for every additional visit.
Approximately 43% of the ACS patients in our study 
were readmitted to the hospital for any cause and 38% for a 
cardiac reason within 1 year. These figures represent a higher 
proportion of rehospitalized patients than the 30% reported 
by Johnston et al.26 The high percentage of patients with 
diabetes (28%) may have contributed to this result. Of the 
patients who were rehospitalized for a noncardiac reason, 
60% had a comorbidity of diabetes.
While research has shown increased risks other than death 
in ischemic heart disease patients who have altered HRV, such 
as in-hospital complications,6 life-threatening arrhythmias,15 
and ischemia after coronary artery bypass grafting,16 less is 
known about the connection between HRV and the rehospi-
talization of ACS patients. Our study revealed that increased 
NHF and SD12 along with decreased NLF, LF/HF ratio, and 
DFA1 were significantly associated with rehospitalization for 
any cause within 1 year, while controlling for demographic 
and clinical variables, ie, age, sex, living with a significant 
other, CAD history, and diabetes comorbidity.
Erratic rhythm and rehospitalization
While research has established that HF power usually cor-
responds to the underlying parasympathetic modulation 
and respiratory sinus arrhythmia,27 recent findings suggest 
this may not always be the case.13,17,28 High NHF power in 
conjunction with low DFA1 in rehospitalized patients is 
consistent with the finding of erratic rhythm in relation to 
poorer outcomes, described by Stein et al.17 The presence of 
an erratic rhythm may misleadingly elevate values of short-
term HRV indices, such as HF power.17
Cardiovascular Health Study (CHS) investigators exam-
ined autonomic predictors of cardiovascular death with 
24-hour Holter monitoring in 1,429 volunteers;13 30% of 
the group had cardiovascular disease. In a subset of the 
CHS recordings, low NLF, LF/HF ratio, and high NHF were 
associated with low DFA1 and a high degree of disorganized 
heart rate patterns, as seen in Poincaré plots. CHS investiga-
tors found that decreased DFA1 had a strong relationship 
to 12-year mortality.13 In a study of coronary artery bypass 
graft patients, high SD12 on postoperative day 1 predicted 
myocardial ischemia on postoperative day 2 (P 0.01).16 
Low DFA1 in conjunction with high SD12 may be present 
when heart rate patterns are irregular, and this beat-to-beat 
variability may not represent parasympathetic function.17,28 
SD12 captures the scatter of the Poincaré plot by fitting an 
ellipse to the points of the plot (SD1 for the short axis, and 
SD2 for the long one). A normal Poincaré plot is comet or 
cigar shaped. A Poincaré plot of normal RR intervals that is 
associated with an erratic rhythm will be far more scattered 
(because of the jumps in N–N interval durations from one to 
the next), and as a result, SD1 will be bigger relative to SD2 
when compared to a normal plot. This is reflected in the SD12 
ratio. Our findings in ACS patients who were rehospitalized 
were comparable to the previous research,17,28 and could 
indicate that a high degree erratic rhythm was present.
1-year all-cause mortality
Our results indicated that abnormal HRV during the very 
early stages of ACS is prognostic of mortality. We found 
statistically significant associations with death and low 
SDANN, ULFlog, TPlog, and high SD12.
SDANN 53 ms was significantly associated with all-
cause death. Relative risk of death was almost four times 





higher for patients with measures below, compared to those 
with measures above, that cut-point. In a study of cardiac 
resynchronization therapy’s effectiveness for improving 
HRV in 113 heart failure patients, Fantoni et al29 found that 
SDANN was the first measure to increase after therapy. Lack 
of a positive change in SDANN helped identify those who 
were at increased risk for adverse events, including hospi-
talization and cardiovascular death.29 In addition, SDANN 
and ULF correspond to each other mathematically,1 and low 
ULFlog has been significantly associated with mortality in 
prior research.4
In a 2-year multicenter study (Autonomic Tone and 
Reflexes After Myocardial Infarction),5 HRV was examined 
in 1,284 participants who had had an MI within the previ-
ous 28 days. SDNN 70 ms was significantly associated 
with higher mortality over 21 months compared to those 
with higher values.5 A meta-analysis by Buccelletti et al8 of 
21 studies showed that in MI patients with SDNN 70 ms, 
risk of death was four times higher over 3 years compared to 
those with higher SDNN. In our study, low SDNN was associ-
ated with cardiac death and TP, which corresponds to SDNN,1 
and which was significantly lower in all nonsurvivors. Patients 
with TPlog 8.4 ms
2 had a relative risk of all-cause death 
nearly four times greater than those with higher values.
Our results were in accordance with Cardiac Arrhythmia 
Suppression Trial (CAST) investigators who found high SD12 
was associated with mortality over a year (P 0.002).7
Identification of clinically relevant  
HRV variables
Many factors contribute to the complexity of ACS out-
comes, as clinical practice guidelines for ACS management 
emphasize.11 We identified several HRV variables that, in 
conjunction with clinical factors, potentially could serve as 
useful tools in distinguishing groups of higher risk patients. 
Specifically, our analysis showed that NHF 42 ms2 and 
NLF 50 ms2, LF/HF 0.5, DFA1 0.95, and SD12 0.45 
predicted rehospitalization in a multivariate model including 
sex, age, living situation, CAD history, and diabetes.
Previous research has provided evidence that HRV can be 
altered in conjunction with diabetes30 or heart disease.3–8,15–20 In 
particular, the presence of an interaction between NHF 42 ms2 
and diabetes suggests that risk of adverse outcomes with one 
of these predictors may vary depending upon presence of the 
other, and risk is highest when both conditions are present. Early 
assessment of HRV in ACS may provide additional information 
to determine rehospitalization risk in ACS patients who have 
diabetes or CAD history. Additionally, our finding that patients 
with diabetes made up a large portion of patients readmitted 
to the hospital for noncardiac causes may lend support to the 
inclusion of all-cause outcomes during risk assessment.
Finally, we found that the identification of abnormal HRV, 
such as ULFlog 8 ms
2, TPlog 8.4 ms
2, or SDANN 54 ms, 
in conjunction with elevated troponin I, might aid in assessing 
the prognosis for MI patients. Filipovic et al31 demonstrated 
that elevated troponin postoperatively and decreased LF/HF 
ratio ( 2) preoperatively were independent risk factors for 
1-year mortality after noncardiac surgery in patients with a 
CAD history. While we found that low LF/HF was associated 
with rehospitalization, our results support the premise that 
HRV variables serve as indicators of increased risk.
Poincaré plots
Poincaré plots to aid in detecting low- versus high-risk 
patients could potentially serve as an adjunct tool.17,27 Huikuri 
et al15 used Poincaré plots to distinguish between abnormali-
ties in post-MI patients with history of ventricular arrhythmia 
compared to a post-MI group without that history. After an 
episode of ventricular tachycardia induced via electrical 
stimulation, the researchers noted that the group in which 
ventricular tachycardia was provoked displayed abnormal 
patterns in the hour prior to development of the arrhythmia.15 
We found that Poincaré plots of patients who were rehospi-
talized or who died varied from those who were event-free, 
and displayed patterns associated with poorer outcomes. 
The plots provided visual references and potentially useful 
illustrations (Figure 5).
Implications
HRV has become recognized as a reflection of cardiac 
autonomic modulation.2,32 Mechanisms behind the physi-
ological interplay between the sympathetic and parasym-
pathetic branches – along with the role of HRV patterns in 
prognostication of health and disease – warrant continuing 
investigation.
Practice standards recommend 24 hours of cardiac moni-
toring for ACS patients after ED presentation.33 Our Holter 
findings suggest that use of HRV measurements to assist in 
identifying patients at highest risk for adverse events might 
be a practical addition to continuous ECG monitoring.
Note, however, that our univariate analyses did not find 
therapies, such as beta blocker administration or percutaneous 
coronary intervention, to be significantly associated with the 
outcomes. The authors speculate that this might be due to 
the large percentage of patients who received beta blocker 
medication, including intravenous and oral administration, 
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rendering the statistical analysis less than significant.22 Our 
findings are unlike the significant findings in previous stud-
ies related to these interventions.34,35 In a similar fashion, the 
continuous ECG recordings throughout the percutaneous 
coronary intervention procedures may have effectively muted 
the HRV results because abnormal HRV prior to the interven-
tion could have been offset by the restored HRV afterward, 
even though improvement in HRV would not necessarily be 
immediate.35 Therefore, our statistical results do not reflect 
the clinical benefit that these therapies may provide.
Limitations
This was a retrospective analysis of data collected from 
2002–2004, and practice standards have changed during 
the ensuing years. Only 193 of 279 ACS patients had 
sufficient ECG recording time and analyzable signals, 
reflecting potential challenges in obtaining accurate data 
for assessment. HF and LF power were measured in 
5-minute segments and averaged over the entire recording 
time. While this method of computing frequency domain 
variables has been used by numerous researchers,13,14,17,21 
others have described a brief 5-minute recording as simple 
and efficient.8 Clearly, it was not possible to control for 
all potentially confounding factors, including medication 
administration and interventional therapies. Follow up of 
patients in our study identified those who were readmitted 
to the hospital for a cardiac reason, and this was confirmed 
in the medical record whenever possible. However, the exact 
nature of the cardiac rehospitalization was not always avail-
able. Finally, conclusions about HRV in relation to mortality 
are tempered by low power.
Conclusion
There are a variety of HRV measurement methods, and 
previous investigators have suggested that the measure-
ments could be complimentary.2 Our findings support 
the suggestion that there may not be one primary HRV 
variable associated with increased risk of rehospitaliza-
tion or death. To serve as a useful tool, HRV needs to be 
assessed within the context of the patient’s whole clinical 
profile. Time domain, frequency domain, and nonlinear 
HRV in conjunction with clinical indicators hold potential 
for assisting in the risk stratification of ACS patient sub-
groups, such as those with diabetes or prior CAD. HRV 
measured close to ACS symptom onset could provide 
additional useful information to assess ACS patients’ 
risk of rehospitalization and/or death within 1 year of 
ED presentation.
Future directions
The urgent and immediate therapies that patients are pro-
vided with in the ED and intensive care unit make this a 
challenging environment within which to conduct research. 
Patients admitted to the ED may have a highly activated 
sympathetic response to their situation and environment. It 
is important to take these factors into consideration in stud-
ies that attempt to capture an accurate reflection of patients’ 
autonomic function.
Areas for future research might include studies to:
Determine the effects on HRV of cardiac drug therapies, 
including route, dose, and type;
Identify the impact of patients’ sympathetic response in 
the ED; and
Examine the cost effectiveness of HRV measurements 
incorporated into routine cardiac monitoring of hospital-
ized ACS patients.
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